EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Allergic rhinitis activity and efficacy of 300 IR house dust mite sublingual immunotherapy tablet in pediatrics

Philippe Devillier, Mitsuhiro Okano, Giorgio Walter Canonica iD, Silvia Scurati, Josiane Cognet-Sicé, Catherine Gentil, Kwok Yan, Julien Cottet, Eric Fromentin, Pascal Demoly, Oliver Pfaar, Yoshitaka Okamoto

Pediatric Allergy and Immunology · 2026-04 · 37 (4)

DOI: 10.1111/pai.70339 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 12.04.2026. Verfasst von Philippe Devillier und 11 weiteren Autor:innen. Beteiligte Einrichtung: VIM Suresnes, Respiratory Pharmacology Research Unit, UMR_0892, INSERM ERL U1369, University Versailles-Saint Quentin & Paris-Saclay & Department of …. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Rhinitis, Allergic, Antigens, Dermatophagoides, Pyroglyphidae. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stallergenes Greer, Stallergenes Greer France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

House dust mite (HDM) allergic rhinitis (HDM‐AR) fluctuates over time with exposure conditions, making disease activity assessment essential when demonstrating treatment efficacy. We conducted post hoc tertile analyses to more accurately assess the efficacy of 300 IR HDM sublingual immunotherapy (SLIT) tablet in moderate‐to‐severe HDM‐AR pediatric patients during periods of increased disease activity.

Methods

Data from two Japanese randomized controlled trials of 300 IR HDM SLIT‐tablet were used to assess the average adjusted symptom score (AASS) and average combined symptom and medication score (ACSMS). To determine the impact of HDM‐AR activity, placebo group scores during the primary period (end of treatment) at each center were ranked from lowest to highest to establish three tertiles. Scores differences between SLIT and placebo were analyzed in each tertile using ANCOVA.

Results

The first analysis included patients aged 5–16 years (300 IR = 193, placebo = 210). During the primary period, the effect of the SLIT‐tablet, estimated at −13.1% (AASS) and −12.9% (ACSMS) versus placebo overall, was more pronounced in the highest tertile (relative differences −27.3% and −28.5%, respectively), with similar results across age groups. The second analysis including a pool of adolescents (300 IR = 120, placebo = 135) showed an overall effect of −19.9% (AASS) and −21.2% (ACSMS) with 300 IR versus placebo, with again greater improvements in the highest tertile (−32.5% and −34.1%, respectively).

Conclusion

The greatest improvements occurred in the tertile where pediatric patients exhibited higher disease activity. This underscores the true efficacy of 300 IR HDM SLIT‐tablet during periods when patients experience the most troublesome symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sublingual ImmunotherapyRhinitis, AllergicAntigens, DermatophagoidesPyroglyphidaeDust Mite AllergyHumansChildAnimalsAdolescentChild, PreschoolFemaleTreatment OutcomeMaleTabletsJapan

Stichwörter der Autor:innen

efficacyhouse dust mitespediatricrhinitis, allergicsublingual immunotherapy

Substanzen

Antigens, DermatophagoidesTablets

Autor:innen und Institutionen

  • VIM Suresnes, Respiratory Pharmacology Research Unit, UMR_0892, INSERM ERL U1369, University Versailles-Saint Quentin & Paris-Saclay & Department of Airway Diseases, Hôpital Foch, Suresnes, France.
  • Department of Otorhinolaryngology, School of Medicine, International University of Health and Welfare, Narita, Japan.
  • Department of Biomedical Sciences, Humanitas University Personalized Medicine, Pieve Emanuele, Milan, Italy.
  • Asthma & Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
  • Stallergenes Greer, Antony, France.
  • Axiodis, Toulouse, France.

ORCID-Profile: Giorgio Walter Canonica

Förderung

  • Stallergenes Greer
  • Stallergenes Greer France

Zitieren

APA

Devillier, P., Okano, M., Canonica, G. W., Scurati, S., Cognet-Sicé, J., Gentil, C., Yan, K., Cottet, J., Fromentin, E., Demoly, P., Pfaar, O., & Okamoto, Y. (2026). Allergic rhinitis activity and efficacy of 300 IR house dust mite sublingual immunotherapy tablet in pediatrics. Pediatric Allergy and Immunology, 37(4). https://doi.org/10.1111/pai.70339

Vancouver

Devillier P, Okano M, Canonica GW, Scurati S, Cognet-Sicé J, Gentil C, et al. Allergic rhinitis activity and efficacy of 300 IR house dust mite sublingual immunotherapy tablet in pediatrics. Pediatric Allergy and Immunology. 2026;37(4). doi:10.1111/pai.70339

BibTeX
@article{Devillier2026,
  author = {Devillier, Philippe and Okano, Mitsuhiro and Canonica, Giorgio Walter and Scurati, Silvia and Cognet-Sicé, Josiane and Gentil, Catherine and Yan, Kwok and Cottet, Julien and Fromentin, Eric and Demoly, Pascal and Pfaar, Oliver and Okamoto, Yoshitaka},
  title = {Allergic rhinitis activity and efficacy of 300 IR house dust mite sublingual immunotherapy tablet in pediatrics},
  journal = {Pediatric Allergy and Immunology},
  year = {2026},
  volume = {37},
  number = {4},
  doi = {10.1111/pai.70339}
}
Kostenlos starten →